October 2018

XtalPi integrates quantum physics and AI to create computational drug discovery and development applications that accurately predict important drug properties of small molecules, helping researchers accelerate and de-risk pharmaceutical innovations.

XtalPi announces the closing of $46 million Series B-1 extension to drive growth and accelerate platform development

CAMBRIDGE, Mass., Oct 24, 2018 – XtalPi Inc, a computation-driven biotech startup integrating quantum physics, artificial intelligence (AI), and cloud computing to empower pharmaceutical research, today announced a Series B-1 extension financing of $46 million to support XtalPi’s continuous market growth and expand the application...

Read More